Celcuity Inc. (CELC)
$
104.79
-1.99 (-1.90%)
Key metrics
Financial statements
Free cash flow per share
-3.2353
Market cap
4.8 Billion
Price to sales ratio
0
Debt to equity
2.7389
Current ratio
12.2576
Income quality
0.8889
Average inventory
0
ROE
-1.7900
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Celcuity Inc., a clinical stage biotechnology company focused on developing molecularly targeted therapies for cancer patients in the United States, reported an income before tax of -$111,779,105.00 showcasing its pre-tax profitability. Despite this positive indication, the company reported a net loss of -$111,779,105.00 indicating challenges in its operations. The earnings per share (EPS) is reported at -$2.83 which highlights the company's profitability on a per-share basis. Additionally, the company reported depreciation and amortization expenses of $129,947.00 reflecting the wear and tear of its assets. The income before tax ratio stands at 0.00 reflecting the pre-tax margin. Celcuity's CELsignia diagnostic platform allows for the identification of specific abnormal cellular processes in patients’ cancer using their living tumor cells, enabling targeted therapy selection. Among its drug candidates, Gedatolisib selectively targets various class I isoforms of PI3K and mammalian target of rapamycin, particularly focusing on hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also advancing the CELsignia MP test, a qualitative laboratory-developed test to measure HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Furthermore, Celcuity has a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Founded in 2011 and headquartered in Minneapolis, Minnesota, the company operates within a crucial and transformative landscape of cancer treatment. In terms of its market positioning, the stock is affordable at $51.88 making it suitable for budget-conscious investors. With a low average trading volume of 824,480.00 the stock indicates lower market activity, suggesting a potentially less volatile investment environment. With a market capitalization of $4,848,765,231.00 the company is classified as a small-cap player in the industry, where it is recognized as a key contributor shaping the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth, providing promising avenues for investment as it continues to develop its targeted therapies and diagnostic platforms.
Is Celcuity Inc. (CELC) a good investment?
Investing in Celcuity Inc. (CELC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is Celcuity Inc. (CELC)'s stock forecast?
Analysts predict Celcuity Inc. stock to fluctuate between $7.58 (low) and $120.32 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Celcuity Inc.'s market capitalization?
As of 2026-02-20, Celcuity Inc.'s market cap is $4,848,765,231, based on 46,271,259 outstanding shares.
How does Celcuity Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Celcuity Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Celcuity Inc. (CELC) stock?
To buy Celcuity Inc. (CELC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CELC. Place an order (Market, Limit, etc.).
What is the best time to invest in Celcuity Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Celcuity Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.83 | Growth: 5.20%.
Where can I find Celcuity Inc.'s investor relations reports?
Visit https://www.celcuity.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Celcuity Inc.?
You can explore historical data from here
What is the all-time high and low for Celcuity Inc. stock?
All-time high: $120.32 (2026-01-27) | All-time low: $4.81 (2022-05-17).
What are the key trends affecting Celcuity Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
zacks.com
Here is how Celcuity, Inc. (CELC) and Day One Biopharmaceuticals, Inc. (DAWN) have performed compared to their sector so far this year.
fool.com
David Dalvey sold 20,000 shares indirectly on Jan. 27, 2026 for a transaction value of ~$2.4 million, at a weighted average price of $120.03 per share. The transaction represented 18.18% of Dalvey's total indirect holdings prior to the sale, reducing his stake from 110,000 to 90,000 shares.
globenewswire.com
FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026 MINNEAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for filing its New Drug Application (“NDA”) for gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), PIK3CA wild-type advanced breast cancer (“ABC”). The FDA granted Priority Review and assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of July 17, 2026.
zacks.com
CELC shares surge as NDA filing and strong phase III data boost optimism around gedatolisib's potential.
seekingalpha.com
Celcuity Inc. surged over 750% in 2025 on best-in-class Phase 3 data for gedatolisib in HR+/HER2- advanced breast cancer. GEDATOLISIB demonstrated superior efficacy and safety versus standards of care, with median PFS of 9.3 months in VIKTORIA-1 and favorable adverse event profile. Management projects peak revenues of $2.5–$3 billion for gedatolisib; current cash position is nearly $500 million, supporting regulatory and commercial milestones.
globenewswire.com
MINNEAPOLIS, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated results from the randomized, Phase 3 VIKTORIA-1 trial for gedatolisib, a multi-target PI3K/AKT/mTOR (“PAM”) inhibitor, in adults with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-“), PIK3CA wild-type (“WT”), advanced breast cancer (“ABC”), following progression on, or after, treatment with a CDK4/6 inhibitor and an aromatase inhibitor. The additional study results were presented in an oral presentation session at the 2025 San Antonio Breast Cancer Symposium (“SABCS”) today, Thursday, December 11.
marketbeat.com
Many investors have profited from the artificial intelligence (AI) trade in 2025. But there have been several up-and-coming stocks in other sectors that have posted impressive gains this year.
fool.com
A top biotech fund just made a bold move while Celcuity trades near record highs—here's what they might see coming next.
fool.com
New York City-based Apis Capital Advisors added 776,000 shares in CELC during the third quarter, establishing a position valued at $38.3 million. The new stake represents 8.5% of Apis' reportable assets under management at quarter-end.
See all news
